Progress in prevention and treatment of malaria

Current Opinion in Infectious Diseases

Volumn 9, Issue 5, 1996, Pages 319-329

  Baird, J Kevin ^a   Hoffman, Stephen L ^a  

^a NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ARTEMETHER; ARTEMISIN; ARTESUNATE; ATOVAQUONE; CHLOROQUINE; CLINDAMYCIN; DOXYCYCLINE FOSFATEX; FANSIDAR; INSECTICIDE; MALARIA VACCINE; MALOPRIM; MEFLOQUINE; PENTOXIFYLLINE; PRIMAQUINE; PROGUANIL; QUININE;

BED; ENDEMIC DISEASE; HUMAN; IMMUNITY; MALARIA; MALARIA CONTROL; PLASMODIUM FALCIPARUM; REVIEW; SIDE EFFECT; TROPICS;

EID: 0029800949     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199610000-00007     Document Type: Review

References (91)

1. World Health Organization: Fact Sheet No. 94, November 1995, Geneva.
2. van Dijk MR, Waters AP, Janse CJ: Stable transfection of malaria parasite bloodstages. Science 1995, 268:1358-1362. This study reports on a technique allowing the selective inactivation of genes in viable parasites in situ, a major breakthrough in the understanding of these parasites.
3. van Dijk MR, Janse CJ, Waters AP: Expression of a Plasmodium gene introduced into subtelomeric regions of Plasmodium berghei chromosomes. Science 271:662-665.
4. Wu Y, Sifri CD, Lei HH, Su X, Wellems TE: Transfection of Plasmodium falciparum within human red blood cells. Proc Natl Acad Sci U S A 1995, 92:973-977. This study reports on another technique allowing the selective inactivation of genes in variable parasites in-situ, a major breakthrough in the understanding of these parasites.
5. Wu Y, Kirkman LA, Wellems TE: Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc Natl Acad Sci U S A 1995, 93:1130-1134.
6. Moore JM, Kumar N, Shultz LD, Rajan TV: Maintenance of the human malarial parasite, Plasmodium falciparum, in SCID mice and transmission of gametocytes to mosquitoes. J Exp Med 1995, 181:2265-2270. This study reports on model system allowing the development of P. falciparum in severely immunodeficient mice, a potentially revolutionary technology.
7. Willimann K, Matile H, Weiss NA, Imhof BA: In vivo sequestration of Plasmodium falcifarum-infected human erythrocytes: a severe combined immunodeficiency mouse model for cerebral malaria. J Exp Med 1995, 182:642-653.
8. Badell E, Pasquetto V, Eling W, Thomas A, Druilhe P: Comment: Human Plasmodium liver stages in SCID mice: a feasible model? Parasitol Today 1995, 11:169-171.
9. Choi HW, Breman JG, Teutsch SM, Liu S, Hightower AW, Sexton JD: The effectiveness of insecticide-impregnated bednets in reducing cases of malaria infection: a meta-analysis of published results. Am J Trop Med Hyg 1995, 52:377-382.
10. Kroeger A, Mancheno M, Alarcon J, Pesse K: Insecticide-impregnated bednets for malaria control: varying experiences from Ecuador, Columbia and Peru concerning acceptability and effectiveness. Am J Trop Med Hyg 1995, 53:313-323.
11. Huailu C, Wen Y, Wuanmin K, Chongyi L: Large-scale spraying of bednets to control mosquito vectors and malaria in Sichuan, China. Bull WHO 1995, 73:321-328.
12. Dapeng L, Deling L, Rengua Y, Peng L, Zueguang H, Aimin L, Lei W, Changyin G, Shaowen Z, Hongru H, Leyuan S: Alphamethrin-impregnated bednets for malaria control and mosquito control in China. Trans R Soc Trop Med Hyg 1994, 88:625-628.
13. Jaenson TGT, Gomes MJ, Barreto dos Santos RC, Petrarca V, Fortini D, Evora J, Crato J: Control of endophagic Anopheles mosquitoes and human malaria in Guinea-Bissau, West Africa by permethrin-treated bednets. Trans R Soc Trop Med Hyg 1994, 88:620-624.
14. D'Alessandro U, Olaleye BO, McGuire W, Langerock P, Bennett S, Aikins MK, Thompson MC, Cham MK, Cham BA, Greenwood BM: Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bednet programme. Lancet 1995, 345:479-483. The authors analyse the effectiveness of an ITBN programme instituted by Gambian authorities, finding a 25% reduction in all-case mortality compared with villages that did not receive ITBN.
15. Binka FN, Kubaje A, Adjuik M, Williams LA, Lengeler C, Maude GH, Armah GE, Kajihara B, Adiamah JH, Smith PG: Impact of permethrin-impregnated bednets on child mortality in Kassena-Nankana district, Ghana: a randomized controlled trial. Trop Mod Int Hlth 1996, 1:147-154. The authors describe the effect of ITBN on all-cause mortality among children aged 6 months to 4 years. A 17% reduction was measured, almost all of which occurred among children less than 2 years old.
16. Hoffman SL, Miller LH: Perspectives on malaria vaccine development. Ch. 1. In Malaria vaccine development: a multi-immune approach. Edited by Hoffman SL. Washington DC: American Society for Microbiology; 1995:1-13.
17. Beadle C, McElroy PD, Oster CN, Beier JC, Oloo AJ, Onyango FK, Chumo DK, Bales JD, Sherwood JA, Hoffman SL: Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design. J Infect Dis 1995, 172:1047-1054. A quantitative analysis of the impact of entomological inoculation upon parasite densities and how these parameters impact vaccine trial endpoint frequencies and sample size.
18. McElroy PD, Beier JC, Oster CN, Beadle C, Sherwood JA, Oloo AJ, Hoffman SL: Predicting outcome in malaria: correlation between rate of exposure to infected mosquitoes and level of Plasmodium falciparum parasetemia. Am J Trop Med Hyg 1994, 51:523-532.
19. Hill AVS, Elvin J, Willis AC, Aidoo M, Allsopp CEM, Gotch FM, Gao M, Takiguchi M, Greenwood BM, Townsend ARM et al.: Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992, 360:434-439.
20. Hoffman SL, Franke ED, Hollingdale MR, Druilhe P: Attacking the infected hepatocyte Ch. 3. In Malaria vaccine development: a multi-immune response approach. Edited by Hoffman SL. Washington, DC: American Society for Microbiology; 1995:35-75. This is a comprehensive review of the infected hepatocyte as a target of immunization.
21. Roggero M, Filippi B, Church P, Hoffman SL, Blum-Tirouvanziam U, Lopez JA, Esposito F, Matile H, Reymond CD, Fasel N et al.: Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Molec Immunol 1995, 32:1301-1309.
22. Scheller L, Azad AF: Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Nat Acad Sci U S A 1995, 92:4066-4068. The authors show that the persistence of intrahepatic P. berghei following inoculation with irradiated sporozoites is required for the induction of protection.
23. Aidoo M, Lalvani A, Allsopp CEM, Plebanski M, Meisner SJ, Krausa P, Browning M, Morris-Jones S, Gotch F, Fidock DA et al.: Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 1995, 345:1003-1007. Identification of CTL epitopes in LSA-1, CSP, SSP2/TRAP and STARP of P. falciparum by analysis of HLA binding motifs, represents an application of reverse immunogenics in identifying candidates suitable for the administration of a malaria vaccine
24. + dependent cytotoxic T lymphocyte epitopes were mapped in this study using cells from humans immunized with irradiated sporozoites of P. falciparum.
25. Wizel B, Houghten R, Church P, Tine JA, Lanar DE, Gordon DM, Ballou WR, Sette A, Hoffman SL: HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. J Immunol 1995, 155:766-775. This study is a demonstration of HLA-A2-restricted CTL responses among volunteers immunized with SSP2.
26. Blum-Tirouvanziam U, Servis C, Habluetzel A, Valmori D, Men Y, Esposito F, Nero LD, Holmes N, Fasel N, Corradin G: Localization of HLA-A2.1 -restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum J Immunol 1995, 154:3922-3931.
27. Charoenvit Y, Mellouk S, Sedegah M, Toyoshima T, Leef MF, De la Vega P, Beaudoin RL, Aikawa M, Fallarme V, Hoffman SL: Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody Exp Parasitol 1995, 80:419-429. MAbs to a protein on blood-stage and liver-stage parasites block malaria infections in mice.
28. Sina BJ, Wright C, Atkinson CT, Ballou R, Aikawa M, Hollingdale M: Characterization of a sporozoite antigen common to Plasmodium falciparum and Plasmodium berghei Mol Biochem Parasitol 1995, 69:239-246.
29. Krzych U, Lyon JA, Jareed T, Schneider I, Hollingdale MR, Gordon DM, Ballou WR: T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. J immunol 1995, 155:4072-4077.
30. Wang R, Charoenvit Y, Corradin G, Porozzi R, Hunter RL, Glenn G, Alving CR, Church P, Hoffman SL: Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J Immunol 1995, 154:2784-2793.
31. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG, Yuan G, Hollingdale M, Slaoui M et al.: Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995, 171:1576-1585. This paper outlines a trial of a pre-erythrocytic vaccine candidate (RTSS) showing no protection (0/7) with alum but protection (2/7) with alum plus a deacylated monophosphoryl lipid A.
32. + T cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med 1996, 183:1739-1746. This study is a demonstration that multi-gene DNA vaccination circumvents genetic restriction of protection of mice against P. yoelii.
33. Hoffman SL, Doolan DL, Sedegah M, Gramzinski R, Wang H, Gowda K, Hobart P, Margalith M, Norman J, Hedstrom RC: Nucleic acid malaria vaccines: current status and potential. DNA vaccines. Ann NY Acad Sci 1995, 772:88-94. A current review of DNA vaccines.
34. Alonso PL, Smith T, Armstrong Schellenberg JRM, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C et al.: Randomized trial of efficacy of Spf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994, 344:1175-1181.
35. D'Alessandro U, Leach A, Drakeley CJ, Bennett S, Olaleye BO, Fegan GW, Jawara M, Langerock P, George MO, Targett GAT, Greenwood BM: Efficacy trial of malaria vaccine Spf66 in Gambian infants. Lancet 1995, 346:462-467. A randomized and double-blinded placebo-controlled trial of SR66 in an area of moderate infection pressure in the Gambia showing essentially no protection among infants (3% efficacy).
36. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P: Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995, 182:409-418. Studies of antibody-dependent cellular inhibition mediated by monocytes against P. falciparum in vitro suggesting that the merozoite, rather than the infected erythrocyte is the target of antibody-dependent cellular inhibition, and that antibody-dependent cellular inhibition is upregulated by IFN-γ and downregulated by IL-4.
37. 19, the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun 1995, 63:456-466.
38. Udhayakumar V, Anyona D, Kariuki S, Shi YP, Bloland PB, Branch OH, Weiss W, Nahlen BL, Kaslow DC, Lal AA: Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol 1995, 154:6022-6030.
39. Daly TM, Long CA: Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol 1995, 155:226-243.
40. Farley PJ, Long CA: Plasmodium yoelii yoelii 17XL MSP-1: fine specificity mapping of a discontinuous, disulfide-dependent epitope recognized by a protective monoclonal antibody using expression PCR (E-PCR). Exp Parasitol 1995, 80:328-323.
41. Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Purdue-Greenfield, Miller LH, Kaslow DC: Immunogenicity and in-vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Molec Med 1995, 1:325-332. A trial demonstrating immunogenicity and efficacy of a recombinant MSP-1 vaccine in monkeys.
42. Ntoumi F, Contamin H, Rogier C, Bonnefoy S, Trape JF, Mercereau-Puijalon O: Age dependent carriage of multiple Plasmodium falciparum merozoite surface antigen-2 alleles in asymptomatic malaria infections. Am J Trop Med Hyg 1995, 52:81-88.
43. Engelbrecht F, Felger I, Genton G, Alpers M, Beck HP: Plasmodium falciparum: malaria morbidity is associated with specific merozoite surface antigen 2 genotypes. Exp Parasitol 1995, 81:90-96.
44. Taylor RR, Smith DB, Robinson J, McBride J, Riley EM: Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the IgG3 subclass. Infect Immun 1995, 63:4382-4388.
45. Oeuvray C, Houharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P: Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994, 84:1594-1602.
46. Camus D, Hedley TJ: A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science 1985, 230:553-556.
47. Sim BKL, Carter JM, Deal CD, Holland C, Haynes JD, Gross M: Plasmodium falciparum: further characterization of a functionally active region of the merozoite invasion ligand EBA-175. Exp Parasitol 1994, 78:259-268.
48. Peterson DS, Miller, Wellems TE: Isolation of multiple sequences from the Plasmodium falciparum genome that encode conserved domains homologous to those in erythrocyte-binding proteins. Proc Natl Acad Sci U S A 1995, 92:7100-7104. The authors of this study describe genes expressing proteins resembling those involved in merozoite-erythrocyte binding. These may represent non-EBA-175 pathways to merozoite invasion already known to exist.
49. Sim BKL: EBA-175: an erythrocyte-binding ligand of Plasmodium falciparum. Parasitol Today 1995, 11:213-217.
50. Baruch DI, Paslolke BL, Singh HB, Bi X, Ma X, Feldman M, Taraschi TF, Howard RJ. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 1995, 82:77-87. The authors of this study describe cloning the genes responsible for antigenic variation in Plasmodium falciparum.
51. Su X, Heatwole VM, Wertheimer SP, Guinet F, Herrfeldt JA, Peterson DS, Ravetch JA, Wellems TE: The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 1995, 82:89-100. The authors of this study demonstrate that var genes express proteins involved in cytoadherence and antigenic variation, key components of the ability of this parasite to avoid a host immune response.
52. Smith JD, Chitnis CE, Craig AG, Roberts DJ, Hudson-Taylor DE, Peterson DS, Pinches R, Newbold CI, Miller LH: Switches in expression of Plasmodium falcinarum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 1995, 82:101-110. The authors show that expression of var gene products are related to cytoadherence and serological phenotypes.
53. Borst P, Bitter W, McCulloch R, Van Leeuwen F, Rudenko G: Antigenic variation in malaria Cell 1995, 82:1-4.
54. Scholander C, Treutiger CJ, Hultenby K, Wahlgren M: Novel fibrillar structure confers adhesive property to malaria-infected erythrocytes. Nature Med 1996, 2:204-208. The authors of this study identify a potentially important new target for anti-disease vaccination.
55. Carlson J, Helmby H, Hill AVS, Brewster D, Greenwood BM, Wahlgren M: Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies. Lancet 1990, 336:1457-1460.
56. Al-Yaman F, Genton B, Mokela D, Raiko A, Kati S, Rogerson S, Reeder J, Alpers M: Human cerebral malaria: lack of significant association between erythrocyte rosetting and disease severity. Trans R Soc Trop Med Hyg 1995, 89:55-58.
57. Udomsangpetch R, Thanikkul K, Pukrittayakamee S, White NJ: Rosette formation by Plasmodium vivax. Trans R Soc Trop Med Hyg 1995, 89:635-637.
58. Kaslow DC. Transmission-blocking vaccines. Ch 8. In Malaria vaccine development: a multi-immune response approach. Edited by Hoffman SL. Washington, DC: American Society for Microbiology; 1995:181-227.
59. Roeffen W, Geeraedts F, Eling W, Beckers P, Kumar N, Lensen T, Sauerwein R: Transmission blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype dependent. Infect Immun 1995, 63:467-471.
60. Ploton IN, Wizel B, Viscidi R, Kumar N: Mapping of the two overlapping linear epitopes in Pfg27 recognized by Plasmodium falciparum transmission-blocking monoclonal antibodies. Vaccine 1995, 13:1161-1169.
61. Snewin VA, Premawansa S, Kapilananda GMG, Ratnayaka L, Udagama PV, Mattei DM, Khouri E, Del Giudice G, Peiris JSM, Mendis KM, David PH: Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector. J Exp Med 1995, 181:357-362.
62. Fryauff DJ, Baird JK, Basri H, Sumawinata I, Purnomo, Richie TL, Ohrt CK, Mouzin R, Church CJ, Richards AL et al.: Randomized placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malarias. Lancet 1995, 346:1190-1193. A regimen of 30 mg primaquine per day given to non-immunes living in hyperendemic Irian Jaya, Indonesia, was well tolerated and provided good protective efficacy (92%). The trial also demonstrates the almost complete ineffectiveness of chloroquine in preventing P. falciparum or P. vivax in this area.
63. Weiss WR, Johnson A, Oloo AJ, Hoffman SL: Daily primaquine is an effective prophylaxis against falciparum malaria in Kenya. J Infect Dis 1995, 171:1569-1575. A randomized, placebo-controlled open trial of primaquine, mefloquine, doxycycline, and chloroquine plus proguanil in school children living in a holoendemic area of Kenya. The placebo group here (vitamin pill) provides attack rates.
64. Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Wiady I, Purnomo, Leksana B, Masbar S, Richie TL et al.: Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 1995, 52:479-484.
65. Boudreau E, Schuster B, Sanchez J, Novakowski W, Johnson R, Redmond D, Hanson R, Dousel L: Tolerability of prophylactic Lariam regimes. Trop Med Parasitol 1993, 44:257-265.
66. Greenwood AM, Menendez C, Alonso PL, Jaffar S, Langerock P, Lulat S, Todd J, M'Boge B, Francis N, Greenwood BM: Can malaria chemoprophylaxis be restricted to first pregnancies? Trans R Soc Trop Med Hyg 1994, 88:681-682.
67. Greenwood BM, David PH, Otoo-Forbes LN, Allen SJ, Alonso PL, Armstrong Schellenberg JR, Byass P, Hurwitz M, Menon A, Snow RW: Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. Trans R Soc Trop Med Hyg 1995, 89:629-633. A retrospective study showing that children taking chemoprophylaxis during the first 5 years of life are not more susceptible to life-threatening illness once the drug has been withdrawn (compared with children who had taken the placebo).
68. Long GW, Fries L, Watt GH, Hoffman SL: Polymerase chain reaction amplification from Plasmodium falciparum on dried blood spots. Am J Trop Med Hyg 1995, 53:216.
69. Li J, Wirtz RA, McConkey GA, Sattabongkot J, Waters AP, Rogers MJ, McCutchan TF: Plasmodium: genus-conserved primers for species identification and quantitation. Exp Parasitai 1995, 81:182-190. A RT-PCR procedure for identifying species of human plasmodia in blood films or dessicated mosquitoes.
70. Kimura M, Miyake H, Kim H-S, Tanabe M, Arai M, Kawai S, Yamane A, Wataya Y: Species-specific PCR detection of malaria parasites by microtiter plate hybridization: clinical study with malaria patients. J Clin Microbiol 1995, 33:2342-2346.
71. Baird JK, Basri H, Subianto B, Fryauff DJ, McElroy PD, Leksana B, Richie TL, Masbar S, Wignall FS, Hoffman SL: Treatment of chloroquine resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 1995, 171:1678-1882. This study reports on the efficacious treatment of chloroquine-resistant P. vivax in northeastern Irian Jaya, Indonesia, using either of two regimens of chloroquine plus primaquine (including two doses once a day of 1 mg/kg plus 0.5/mg/kg primaquine administered in conjunction with chloroquine), or standard halofantrine therapy.
72. Bunnag D, Kanda T, Karbwang J, Thimasarn K, Pungpak S, Harinasuta T: Artemether-mefloquine combination in multidrug resistant falciparum marlaria. Trans R Soc Trop Med Hyg 1995, 89:213-215.
73. Price RN, Nosten F, Luxemberger C, Kham A, Brockman A, Chongsuphajaisiddhi T, White NJ: Artesunate versus artemether in combination with fefloquine for the treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1995, 89:523-527.
74. Hien TT, Arnold K, Hung NT, Loc PP, Dung NT, Cuong BM, Toan LM, Phung MQ, Anh LHV, Mai PP: Single dose aremisinin-mefloquine treatment for acute uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1995, 88:688-691.
75. Sowunmi A, Oduola AMJ: Open comparison of mefloquine, mefloquine\sulfadoxine\pyrimethamine and chloroquine in acute uncomplicated falciparum malaria in children. Trans R Soc Trop Med Hyg 1995, 89:303-305.
76. Mockenhaupt FP: Mefloquine resistance in Plasmodium falciparum. Parasitol Today 1995, 11:248-253.
77. Metzger W, Mordmuller B, Graninger W, Bienzle U, Kremsner PG: High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria in hyperendemic. Antimicrob Agents Chemother 1995, 39:245-246.
78. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG: Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996, 347:1511-1514. A trial of atovaquone plus proguanil among 71 Gabonese adults showing an 87% cure. However, only one of 71 had a recurrent parasitemia and this could have been a reinfection. The remaining subjects 'not cured' were actually lost to follow-up. Thus, 62 of 63 subjects (98%) enrolled and who completed the study did not have recurrent parasitemias within 28 days of therapy.
79. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Cranfield CJ: Clinical studies of atovaquone, alone or in combination with other antimalarial drugs for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996, 54:62-66. A trial of atovaquone alone or in combination with proguanil, doxycycline, tetracycline, or pyrimethamine. Of 104 adults treated with atovaquone plus proguanil, 101 were cured.
80. Blanchard TJ, Mabey DCW, Hunt-Cooke A, Edwards G, Hutchinson DBA, Benjamin S, Chiodini PL: Muttiresistant falciparum malaria cured using atovaquone and proguanil. Trans R Soc Trop Med Hyg 1995, 88:693.
81. Barker RH Jr, Metelev V, Rapaport E, Zamecnik P: Inhibition of Plasmodium falciparum malaria using antisense oligonucleotides. Proc Natl Acad Sci U S A 1996, 93:514-518. Without phosporothioation of antisense oligodeoxynucleotides (PS AS-ODNs), inhibition of P. falciparum in-vitro was not sequence-specific. With phosphorothioation of AS-ODNs, inhibition occurred at lower concentrations and in a sequence-specific manner.
82. Krishna S, Supanaranond W, Pukrittayakamee S, ter Kuile F, Supputamangkol Y, Attatamsoonthorn K, Ruprah M, White NJ: Fever in uncomplicated Plasmodium falciparum infection: effects of quinine and paracetamol. Trans R Soc Trop Med Hyg 1995, 89:197-199.
83. Krishna S, Pukrittayakamee S, Supanaranond W, ter Kuile F, Ruprah M, Sura T, White NJ: Fever in uncomplicated Plasmodium falciparum malaria: randomized double 'blind' comparison of ibuprofen and paracetamol treatment. Trans R Soc Trop Med Hyg 1995, 89:507-509.
84. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C, Winstanley P, Warn P, Peshu N et al.: Indicators of life-threatening malaria in African children. New Engl J Med 1995, 332:1399-1401. A detailed analysis of 1844 Kenyan children with severe malaria revealing risk factors for death, including respiratory distress.
85. Waller D, Krishna S, Crawley J, Miller K, Nosten F, Chapman D, ter Kuile FO, Craddock C, Berry C, Holloway PAH et al.: Clinical features and outcome of severe malaria in Gambian children. Clin Infect Dis 1995, 21:577-587. A detailed analysis of 180 Gambian children with severe malaria revealing risk factors for death, including respiratory distress.
86. Nakazawa S, Looareesuwan S, Fujioka H, Pongponratn E, Luc KD, Rabbege J, Aikawa M: A correlation between sequestered parasitized erythrocytes in subcutaneous tissue and cerebral malaria. Am J Trop Med Hyg 1995, 53:544-546.
87. Phu NH, Day N, Diep PT, Ferguson DJP, White NJ: Intraleukocytic malaria pigment and prognosis in severe malaria. Trans R Soc Trop Med Hyg 1995, 89:200-204.
88. Metzger WG, Morduller BG, Kremsner PG: Malaria pigment in leukocytes. Trans R Soc Trop Med Hyg 1995, 89:637-638.
89. Di Perri G, Di Perri IG, Monteiro GB, Bonora S, Hennig C, Cassatella M, Micciolo R, Venot S, Dusi S, Bessetti D, Concia E: Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. J Infect Dis 1995, 171:1317-1322.
90. Holloway PA, Knox K, Bajaj N, Chapman D, White NJ, O'Brien R, Stacpoole PW, Krishna S: Plasmodium berghei infection: dichloroacetate improves survival in rats with lactic acidosis. Exp Parasitol 1995, 80:624-632.
91. Krishna S, Agbenyega T, Angus BJ, Bedu-Addo G, Ofori-Amanfo G, Henderson G, Szwandt ISF, O'Brien R, Stacpoole PW: Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. Q J Med 1995, 88:341-349.